2,303 results on '"Einsele, H"'
Search Results
2. Real-world analysis of teclistamab in 123 RRMM patients from Germany
3. Tracking the progeny of adoptively transferred virus-specific T cells in patients posttransplant using TCR sequencing
4. POS0241 GENOME-WIDE METHYLATION PROFILES OF PERIPHERAL WHOLE BLOOD IN NEWLY DIAGNOSED GIANT CELL ARTERITIS OR POLYMYALGIA RHEUMATICA
5. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
6. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
7. CAR-T-Zell-Therapie beim multiplen Myelom
8. Dismal prognosis of Pneumocystis jirovecii pneumonia in patients with multiple myeloma
9. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation
10. Treatment of Transplant Eligible Patients with Multiple Myeloma
11. Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
12. Diagnostische und therapeutische Betrachtungen zum Rezidiv des multiplen Myeloms: Eine aktuelle Übersicht
13. Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative forFLT3-ITD,NPM1- or biallelicCEBPA mutations
14. P35 ANALYSIS OF DARATUMUMAB CLINICAL TRIALS: CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH 1-3 PRIOR LINES OF THERAPY
15. P23 EMAGINE/CARTITUDE-6: A RANDOMIZED PHASE 3 STUDY OF DVRD FOLLOWED BY CILTACABTAGENE AUTOLEUCEL VERSUS DVRD FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
16. P46 SEER-MEDICARE DATABASE: REAL-WORLD TREATMENTS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED MULTIPLE MYELOMA TREATED WITH 1–3 PRIOR LINES OF THERAPY, INCLUDING A PI AND IMID
17. HOW TO HARNESS NEW IMMUNOTHERAPIES WITH COMBINATION STRATEGIES?
18. P52 RISK STRATIFICATION COMBINING SKY92 GENE EXPRESSION PROFILING AND TRADITIONAL FISH IN MULTIPLE MYELOMA: THE FIRST PROSPECTIVE EVIDENCE IN THE R2-ISS ERA
19. P45 HIGH-DOSE CARFILZOMIB ACHIEVES SUPERIOR ANTI-TUMOR ACTIVITY OVER LOW-DOSE AND RECAPTURES RESPONSE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA RESISTANT TO LOW-DOSE CARFILZOMIB BY CO-INHIBITING THE B2 AND B1 PROTEASOME SUBUNITS
20. P44 DETECTION OF SOLUBLE BCMA IN TEARS OF MM PATIENTS TREATED WITH BELANTAMAB MAFODOTIN
21. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
22. Second primary malignancies in multiple myeloma: an overview and IMWG consensus
23. Host immune genetic variations influence the risk of developing acute myeloid leukaemia: results from the NuCLEAR consortium
24. Progressive multifocal leukoencephalopathy in a patient post allo-HCT successfully treated with JC virus specific donor lymphocytes
25. Therapie des multiplen Myeloms mit Elotuzumab plus Pomalidomid und Dexamethason
26. Therapie jüngerer Patienten mit multiplem Myelom
27. Algorithmus zur Primärtherapie beim multiplen Myelom
28. Multiples Myelom: Von der lebensverlängernden Therapie zur Heilung
29. CXC-Motiv-Chemokinrezeptor 4-gerichtete Radioligandentherapie bei fortgeschrittenen hämatologischen Neoplasien – Myeloablation, Anti-Lymphom Aktivität und Off-Target-Effekte
30. CXCR4-gerichtete PET/CT in 100 Patient:innen mit Marginalzonenlymphom -Diagnostische Performance, Vorhersagepotenzial und Eignung für CXCR4-Endoradiotherapie
31. Einfluss einer erhöhten Manifestations-Last auf die Ga-68-PentixaFor Biodistribution bei Patient:innen mit Marginalzonenlymphom - Potentielle therapeutische Implikationen
32. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation
33. Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9)
34. Prospective multicentre PCR-based Aspergillus DNA screening in high-risk patients with and without primary antifungal mould prophylaxis
35. Treatment of Transplant Eligible Patients with Multiple Myeloma
36. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT
37. Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
38. Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma
39. Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma
40. IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM)
41. Hyperglycemia as a possible risk factor for mold infections—the potential preventative role of intensified glucose control in allogeneic hematopoietic stem cell transplantation
42. Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors
43. Recording of the regional origin areas of patients from the molecular tumor board to identify the 'white spots' in the service area - a joint initiative of the Bavarian CCC WERA alliance [Abstract]
44. Detection of T-cell immune responses against cytomegalovirus in seronegative healthy blood donors: a potential source for adoptive immune transfer [Abstract]
45. Corrigendum to “Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’”
46. Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations
47. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party
48. How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT
49. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group
50. PB1980: MULTIPLE MYELOMA: ADOPTING MRD BY NEXT GENERATION FLOW CYTOMETRY (NGF) AND FUNCTIONAL IMAGING GUIDED CONSOLIDATION INTO CLINICAL ROUTINE
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.